S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of (Ad)
NASDAQ:VYNT

Vyant Bio - VYNT Stock Forecast, Price & News

$0.82
+0.01 (+1.23%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.80
$0.82
50-Day Range
$0.66
$0.98
52-Week Range
$0.60
$3.24
Volume
18,881 shs
Average Volume
27,888 shs
Market Capitalization
$24.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Vyant Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
265.9% Upside
$3.00 Price Target
Short Interest
Healthy
0.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.01mentions of Vyant Bio in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.56) to ($0.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

494th out of 1,135 stocks

Medical Laboratories Industry

15th out of 28 stocks

About Vyant Bio

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.

Analysts Set New Price Targets

Separately, HC Wainwright lowered their price objective on shares of Vyant Bio to $3.00 and set a "buy" rating for the company in a research note on Tuesday, May 17th.

Vyant Bio Price Performance

Shares of NASDAQ:VYNT traded up $0.01 during midday trading on Friday, hitting $0.82. 18,881 shares of the company traded hands, compared to its average volume of 27,888. Vyant Bio has a 12-month low of $0.60 and a 12-month high of $3.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.74 and a quick ratio of 2.67. The stock has a 50-day moving average price of $0.82 and a 200 day moving average price of $0.95.

Vyant Bio (NASDAQ:VYNT - Get Rating) last announced its quarterly earnings results on Monday, May 16th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.01. The company had revenue of $0.30 million for the quarter, compared to analysts' expectations of $0.30 million. On average, equities research analysts forecast that Vyant Bio will post -0.56 earnings per share for the current fiscal year.

Receive VYNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vyant Bio and its competitors with MarketBeat's FREE daily newsletter.

VYNT Stock News Headlines

Vyant Bio (VYNT) Set to Announce Quarterly Earnings on Monday
See More Headlines
Receive VYNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vyant Bio and its competitors with MarketBeat's FREE daily newsletter.

VYNT Company Calendar

Last Earnings
5/16/2022
Today
8/14/2022
Next Earnings (Confirmed)
8/15/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VYNT
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+265.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-40,860,000.00
Pretax Margin
-1,251.84%

Debt

Sales & Book Value

Annual Sales
$1.15 million
Book Value
$1.08 per share

Miscellaneous

Free Float
26,539,000
Market Cap
$24.12 million
Optionable
Not Optionable
Beta
1.87














VYNT Stock - Frequently Asked Questions

Should I buy or sell Vyant Bio stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vyant Bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VYNT shares.
View VYNT analyst ratings
or view top-rated stocks.

What is Vyant Bio's stock price forecast for 2022?

1 equities research analysts have issued 1-year price targets for Vyant Bio's shares. Their VYNT share price forecasts range from $3.00 to $3.00. On average, they expect the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 265.9% from the stock's current price.
View analysts price targets for VYNT
or view top-rated stocks among Wall Street analysts.

How have VYNT shares performed in 2022?

Vyant Bio's stock was trading at $1.35 on January 1st, 2022. Since then, VYNT stock has decreased by 39.3% and is now trading at $0.82.
View the best growth stocks for 2022 here
.

When is Vyant Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our VYNT earnings forecast
.

How can I listen to Vyant Bio's earnings call?

Vyant Bio will be holding an earnings conference call on Monday, August 15th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Vyant Bio's earnings last quarter?

Vyant Bio, Inc. (NASDAQ:VYNT) posted its quarterly earnings data on Monday, May, 16th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.01. The company had revenue of $0.30 million for the quarter, compared to analysts' expectations of $0.30 million.

What is Vyant Bio's stock symbol?

Vyant Bio trades on the NASDAQ under the ticker symbol "VYNT."

How do I buy shares of Vyant Bio?

Shares of VYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vyant Bio's stock price today?

One share of VYNT stock can currently be purchased for approximately $0.82.

How much money does Vyant Bio make?

Vyant Bio (NASDAQ:VYNT) has a market capitalization of $24.12 million and generates $1.15 million in revenue each year.

How can I contact Vyant Bio?

Vyant Bio's mailing address is 2370 State Route 70 Suite 310, Cherry Hill NJ, 08002. The official website for the company is stemonix.com. The company can be reached via phone at (201) 479-1357, via email at jzimmons@zimmonsic.com, or via fax at 201-528-9201.

This page (NASDAQ:VYNT) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.